ACELYRIN, INC. Common Stock Cash Flow Conversion Efficiency
ACELYRIN, INC. Common Stock cash flow conversion efficiency. Based on the latest financial reports, ACELYRIN, INC. Common Stock (SLRN) has a cash flow conversion efficiency ratio of -0.096x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-38.95 Million) by net assets ($407.23 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of ACELYRIN, INC. Common Stock (2021–2024)
Cash flow conversion efficiency of ACELYRIN, INC. Common Stock from 2021 to 2024. This chart illustrates how ACELYRIN, INC. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of ACELYRIN, INC. Common Stock for real-time trading data and today's change.
ACELYRIN, INC. Common Stock Cash Flow Conversion Ratio Explained
ACELYRIN, INC. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
ACELYRIN, INC. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ACELYRIN, INC. Common Stock ranked by their cash flow conversion efficiency. Also see ACELYRIN, INC. Common Stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Genesis Technology
TWO:6221
|
-0.072x |
|
Bioteque
TWO:4107
|
0.036x |
|
Viking Supply Ships AB (publ)
ST:VSSAB-B
|
0.016x |
|
Sarana Meditama Metropolitan
JK:SAME
|
0.011x |
|
BCEG Environmental Remediation Co. Ltd.
SHE:300958
|
N/A |
|
Hawthorn Bancshares Inc
NASDAQ:HWBK
|
0.087x |
|
Hanoi Beer Alcohol and Beverage JSC
VN:BHN
|
0.141x |
|
Cint Group AB
ST:CINT
|
0.036x |
Annual Cash Flow Conversion Efficiency for ACELYRIN, INC. Common Stock (2021–2024)
The table below shows the annual cash flow conversion efficiency of ACELYRIN, INC. Common Stock from 2021 to 2024. Review ACELYRIN, INC. Common Stock leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $458.29 Million | $-303.92 Million | -0.663x | -156.48% |
| 2023-12-31 | $656.34 Million | $-169.71 Million | -0.259x | -146.82% |
| 2022-12-31 | $-111.39 Million | $-61.52 Million | 0.552x | +366.50% |
| 2021-12-31 | $-42.06 Million | $-4.98 Million | 0.118x | -- |
About ACELYRIN, INC. Common Stock
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, which has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED). Acelyrin, Inc. was incorp… Read more